CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
EN
Home / Newamsterdam Pharma CO N.V. (NAMS) / obicetrapib ezetimibe
Forward catalyst · NAMS

obicetrapib ezetimibe

Sponsor Newamsterdam Pharma CO N.V. · listed as NAMS

READOUT Phase 3 Confidence: medium Source: clinicaltrials

obicetrapib ezetimibe is a clinical-stage drug asset sponsored by Newamsterdam Pharma CO N.V., listed as NAMS. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Nov 2027 (month precision, medium confidence), tied to trial NCT06305559. The asset is in Phase 3 and currently active not recruiting, studied in Lipidemia. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-11-30
As disclosedNov 2027
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06305559
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorNewAmsterdam Pharma
Listed asNAMS
Condition(s)Lipidemia; Coronary Artery Disease; Plaque, Atherosclerotic
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.

Get the full dataset — $499 →   More NAMS catalysts

Related catalysts and sponsor